Lam Research slides as global chip selloff outweighs strong recent fundamentals

Lam Research (LRCX) is down 9.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied mainly to a broad semiconductor selloff rather than a fresh company-specific setback. Pressure across chip and chip-equipment names, combined with profit-taking after a powerful AI-driven run, looks like the most likely explanation.

Details:

LRCX traded sharply lower as semiconductor stocks sold off globally, with investors rotating out of high-multiple AI and memory-related names during a wider risk-off session.

One key pressure point was a steep drop in South Korean equities, including major memory names, which appears to have shaken confidence in the near-term pace of the AI hardware buildout and spilled into U.S. chip suppliers.

Peer weakness mattered: another major wafer-fab-equipment company also fell heavily the same day, reinforcing the view that this was an industry move instead of an isolated Lam event.

Lam’s most recent quarterly release had been strong, with record March-quarter revenue of $5.84 billion, higher margins, and upbeat commentary around AI demand, so today’s decline looks more like a valuation reset or short-term de-risking than a reversal in reported operating performance.

Sources:

Lam Research, Investing.com, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LRCX Insider Trading Activity

$LRCX insiders have traded $LRCX stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by insiders over the last 6 months:

ERIC BRANDT has made 0 purchases and 45 sales selling 144,000 shares for an estimated $47,025,855.
DOUGLAS R BETTINGER (Chief Financial Officer & EVP) has made 0 purchases and 2 sales selling 90,386 shares for an estimated $20,498,812.
NEIL J FERNANDES (Senior Vice President) has made 0 purchases and 2 sales selling 25,829 shares for an estimated $7,007,120.
AVA HARTER (Chief Legal Officer) has made 0 purchases and 3 sales selling 11,510 shares for an estimated $2,818,536.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$LRCX Hedge Fund Activity

We have seen 1,241 institutional investors add shares of $LRCX stock to their portfolio, and 1,211 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,893,278 shares (+25.8%) to their portfolio in Q1 2026, for an estimated $1,417,947,284
JPMORGAN CHASE & CO removed 6,436,253 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $1,101,757,788
GOLDMAN SACHS GROUP INC removed 4,359,777 shares (-29.4%) from their portfolio in Q1 2026, for an estimated $896,806,128
CORIENT PRIVATE WEALTH LLC removed 4,093,544 shares (-78.7%) from their portfolio in Q1 2026, for an estimated $842,042,000
J. STERN & CO. LLP removed 3,439,713 shares (-99.4%) from their portfolio in Q1 2026, for an estimated $707,548,964
CITADEL ADVISORS LLC removed 3,126,734 shares (-73.7%) from their portfolio in Q1 2026, for an estimated $643,169,183
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 2,921,363 shares (-36.7%) from their portfolio in Q1 2026, for an estimated $600,924,369

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LRCX Congressional Stock Trading

Members of Congress have traded $LRCX stock 12 times in the past 6 months. Of those trades, 3 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $LRCX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 9 times. They made 1 purchase worth up to $15,000 on 03/12 and 8 sales worth up to $190,000 on 06/05, 04/27, 02/26, 01/16, 01/08.
REPRESENTATIVE CLEO FIELDS purchased up to $50,000 on 02/03.
SENATOR JOHN BOOZMAN sold up to $15,000 on 01/08.
SENATOR MARKWAYNE MULLIN purchased up to $100,000 on 12/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$LRCX Analyst Ratings

Wall Street analysts have issued reports on $LRCX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 01/29/2026
Goldman Sachs issued a "Buy" rating on 01/29/2026
RBC Capital issued a "Outperform" rating on 01/15/2026
Wells Fargo issued a "Overweight" rating on 01/15/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Mizuho issued a "Outperform" rating on 01/09/2026

To track analyst ratings and price targets for $LRCX, check out Quiver Quantitative's $LRCX forecast page.

$LRCX Price Targets

Multiple analysts have issued price targets for $LRCX recently. We have seen 22 analysts offer price targets for $LRCX in the last 6 months, with a median target of $333.0.

Here are some recent targets:

Vivek Arya from B of A Securities set a target price of $480.0 on 06/23/2026
Joe Quatrochi from Wells Fargo set a target price of $450.0 on 06/22/2026
Atif Malik from Citigroup set a target price of $450.0 on 06/17/2026
Ed Yang from Oppenheimer set a target price of $400.0 on 06/15/2026
Tom O'Malley from Barclays set a target price of $335.0 on 06/11/2026
C.J. Muse from Cantor Fitzgerald set a target price of $425.0 on 06/10/2026
Timothy Arcuri from UBS set a target price of $375.0 on 06/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.